Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

Front Oncol. 2023 May 22:13:1211935. doi: 10.3389/fonc.2023.1211935. eCollection 2023.

Angelo Maiolino^{1

2}, Elaine Sobral Da Costa¹, Alberto Orfao³

¹ Department of Internal Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
² Department of Hematology, Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.
³ Translational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) Institute for Biomedical Research of Salamanca (IBASAL), CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.

No abstract available

Keywords: disease monitoring; flow cytometry; minimal residual disease; multiple myeloma; prognostic factor.

Publication types